

(<http://www.aphanet.org>)

[Home](#) > OK'd for children 2 to 10 years old

Generic Name:

Meningococcal [groups A, C, Y, and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine

Trade Name:

Menveo

Company:

Novartis

Notes:

Approval was based on Phase III trial data involving 5,297 children 2 to 10 years of age proving the safety and immunogenicity of [Menveo](#) compared with the other currently U.S.-licensed ACW-135Y meningococcal conjugate vaccine. The vaccine was initially approved in 2010 for active immunization in adolescents and adults 11 to 55 years of age.

Medication Monitor Categories:

[Supplemental Approvals](#)

Use:

Prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135 in children 2 to 10 years of age

Source URL: <http://www.aphanet.org/supplemental-approvals/okd-children-2-10-years-old>